CD19 and lymphoma: This study describes an empirically discovered CAR architecture that utilizes high basal CAR signaling and costimulation (i.e., “always on”) to drive T-cell proliferation and potent antitumor activity against aggressive CD19+ and CD123+ lymphoma and leukemia cell lines.